SCHEMBL127815

SCHEMBL127815

O=C1NC(=O)C2CCC=CC2N1

nearest known ligand 0.38

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
BACE1 P56817 1/20 0.38
TDP1 Q9NUW8 1/20 0.33
TSHR P16473 1/20 0.33
ALDH1A1 P00352 1/20 0.31
MAPT P10636 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Acetic Acid SCHEMBL1801429 0.91 ALDH1A1 (0.33) BACE1TDP1TSHRALDH1A1MAPT
SCHEMBL5937743 0.84
SCHEMBL5937749 0.84
SCHEMBL5937737 0.84
SCHEMBL2992061 0.71 BACE1 (0.33) BACE1
SCHEMBL179776 0.71 BACE1 (0.33) BACE1
SCHEMBL6457893 0.71
SCHEMBL2992065 0.71 BACE1 (0.33) BACE1
SCHEMBL4619037 0.70
SCHEMBL3495820 0.70

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240190860-A1 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS CHIESI FARMACEUTICI S.P.A. (IT) 2024-06-13 US disclosed
US-11591314-B2 Process for preparing tetrahydrocarbazole carboxamide compound BRISTOL-MYERS SQUIBB COMPANY (US) 2023-02-28 US disclosed
CN-110312713-B Process for preparing tetrahydrocarbazole carboxamide compounds 百时美施贵宝公司 2022-08-12 CN disclosed
US-20210078980-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND BRISTOL MYERS SQUIBB CO (US) 2021-03-18 US disclosed
US-10875843-B2 Process for preparing tetrahydrocarbazole carboxamide compound BRISTOL-MYERS SQUIBB COMPANY (US) 2020-12-29 US disclosed
EP-3558977-B1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND BRISTOL MYERS SQUIBB CO (US) 2020-10-28 EP disclosed
EP-2773623-B1 1-(ARYLMETHYL)-5,6,7,8-TETRAHYDROQUINAZOLINE-2,4-DIONES AND ANALOGS AND THE USE THEREOF IMPACT THERAPEUTICS INC (CN) 2020-04-29 EP disclosed
US-20200109133-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND BRISTOL MYERS SQUIBB CO (US) 2020-04-09 US disclosed
EP-3558977-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND Bristol-Myers Squibb Company (US) 2019-10-30 EP disclosed
WO-2018118830-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND BRISTOL-MYERS SQUIBB COMPANY (US) 2018-06-28 WO disclosed
US-5620976-A PREVENTION AND TREATMENT OF DISEASES DUE TO INSUFFICIENCY OF THE CENTRAL CHOLINE FUNCTIONS EISAI CO., LTD. (JP) 1997-04-15 US disclosed
EP-0748800-A3 Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1996-12-27 EP disclosed
EP-0748800-A2 Pyrimidinedione, pyrimidinetrione, triazinedione, tetrahydroquinazolinedione derivatives as alpha-1-adrenergic receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 1996-12-18 EP disclosed
EP-0742216-A2 Cyclic amide derivatives Eisai Co., Ltd. (JP) 1996-11-13 EP disclosed
US-5521182-A ACETYLCHOLINESTERASE INHIBITORS EISAI CO., LTD. (JP) 1996-05-28 US disclosed
US-5504088-A ACETYLCHOLINE ESTERASE INHIBITORS; ALZHEIMER'S DISEASE AND OTHER DISEASES CAUSED BY A LOW CONCENTRATION OF CHOLINE EISAI CO., LTD. (JP) 1996-04-02 US disclosed
EP-0677516-A1 Cyclic amide derivatives Eisai Co., Ltd. (JP) 1995-10-18 EP disclosed
US-5292735-A Cyclic amide derivatives EISAI CO., LTD. (JP) 1994-03-08 US disclosed
EP-0468187-A2 Cyclic amide derivatives Eisai Co., Ltd. (JP) 1992-01-29 EP disclosed
US-4247296-A Diazo pigments BASF FARBEN & FASERN AG (DE) 1981-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210078980-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND CYP2C8, CYP3A7, PARP8 BACE1 451/4885TDP1 3238/4885TSHR 2283/4885
US-11591314-B2 Process for preparing tetrahydrocarbazole carboxamide compound CYP2C8, CYP3A7, PARP8 BACE1 451/4885TDP1 3238/4885TSHR 2283/4885
US-10875843-B2 Process for preparing tetrahydrocarbazole carboxamide compound CYP2C8, CYP3A7, CDK8 BACE1 563/4885TDP1 3314/4885TSHR 2269/4885
US-20240190860-A1 8-CYCLO-SUBSTITUTED QUINAZOLINE DERIVATIVES AS LPA RECEPTOR 2 INHIBITORS LPAR2, LPAR5, LPAR1 BACE1 3840/4885TDP1 4078/4885TSHR 1479/4885
US-20200109133-A1 PROCESS FOR PREPARING TETRAHYDROCARBAZOLE CARBOXAMIDE COMPOUND CYP2C8, CYP3A7, CDK8 BACE1 563/4885TDP1 3314/4885TSHR 2269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.